img
img
Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma      
Yazarlar (6)
Ahmet Ergin
Prof. Dr. Kemal ÖRNEK Prof. Dr. Kemal ÖRNEK
Kırıkkale Üniversitesi, Türkiye
Güllü Reyhan
Emel Bulcun
Kırıkkale Üniversitesi, Türkiye
Mehmet Savaş Ekici
Kırıkkale Üniversitesi, Türkiye
Aydanur Ekici
Kırıkkale Üniversitesi, Türkiye
Devamını Göster
Özet
Purpose: To investigate the respiratory and cardiovascular effects of switching therapy from topical timolol 0.5% to latanoprost 0.005% in elderly patients with glaucoma.
Methods: Twenty-five patients with primary open-angle glaucoma (POAG) who were treated with topical timolol 0.5% were included in the study. The beta-blocker treatment was ended due to insufficient intraocular pressure (IOP) and systemic or local side effects. The treatment then switched to latanoprost in these patients. All recruited patients underwent a full ocular, cardiovascular, and respiratory examination including spirometry, pulse rate, and blood pressure. All measurements were made 1 day before the beta-blocker treatment was ended and 30 days after the latanoprost treatment was started.
Results: Timolol treatment was associated with numerically but not statistically significant lowered pulse rates, systemic blood pressure, diastolic blood pressure, and reductions in the spirometry measurements. The change to latanoprost treatment was associated with numerical improvement in mean values of spirometric test results. There were no significant differences in changes in mean values of spirometry, pulse rate, or blood pressure. Histamine challenge test was determined to be positive in 16 of 25 patients for timolol, of whom 10 were positive for latanoprost. This was statistically significant (P < 0.05).
Conclusions: Although all the results presented were statistically insignificant, switching to latanoprost treatment may offer some advantages in respiratory and cardiovascular function for elderly people with glaucoma over beta-blocker drugs. Spirometry and the measurement of pulse rate and blood pressure are advised in all patients receiving topical beta-blocker therapy.
Anahtar Kelimeler
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Dergi ISSN 1080-7683 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI
Makale Dili İngilizce
Basım Tarihi 10-2009
Cilt No 25
Sayı 5
Sayfalar 463 / 466
Doi Numarası 10.1089/jop.2008.0137